Skip to main content
. 2014 Nov 5;1329(1):93–106. doi: 10.1111/nyas.12567

Figure 2.

Figure 2

Kaplan–Meier curves for the primary efficacy and safety outcomes in the phase III warfarin-controlled trial of apixaban for stroke prevention in atrial prevention (ARISTOTLE trial). The primary efficacy outcome (Panel A) was stroke or systemic embolism. The primary safety outcome (Panel B) was major bleeding, as defined according to the criteria of the ISTH. Modified, with permission, from Granger et al.29